期刊文献+

腹膜透析治疗糖尿病肾病与非糖尿病肾病尿毒症患者的对比分析 被引量:2

下载PDF
导出
摘要 目的比较糖尿病肾病与非糖尿病肾病尿毒症腹膜透析患者的一般情况,分析维持性腹膜透析治疗的并发症及预后。方法回顾性分析180例腹膜透析患者,其中糖尿病肾病尿毒症患者48例(糖尿病肾病组),非糖尿病肾病尿毒症患者132例(非糖尿病肾病组)。记录患者初始透析时的一般资料、临床及实验室指标,对比分析2组患者的营养状态及合并症情况。结果2组患者年龄、平均透析时间、血磷水平、钙磷乘积、血白蛋白水平及腹膜炎发病率有明显差异(P<0.05),血钙水平及血红蛋白水平相似(P>0.05)。血白蛋白水平高的糖尿病肾病患者腹膜炎发病率与非糖尿病肾病组相似(P>0.05)。结论与非糖尿病肾病尿毒症腹膜透析患者相比,糖尿病肾病尿毒症患者的年龄较大,透析持续时间较短,营养不良和腹膜炎的发生率较高,腹膜炎发病率与低蛋白血症明显相关。
出处 《实用临床医学(江西)》 CAS 2008年第12期41-42,共2页 Practical Clinical Medicine
  • 相关文献

参考文献6

  • 1Mujais S,Nolph K,Gokal R, et al. Evalution and Management of Ultra-filtration Problem in Peritoneal Dialysis, Internation Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritonea Dialysis[J]. Petit Dial Int, 2000,20(S 4) : S5-S21.
  • 2Viglino G,Canearini G C,Catizone L,et al. Ten Years Experience of APD in Diabetics:Comparison of Results with Non Diabeties[J]. Nephrol Dial Transplant, 1994,9 (10) : 1443-1448.
  • 3范敏华.腹膜透析钙磷代谢[J].中国血液净化,2004,3(12):639-642. 被引量:4
  • 4Kawaguchi Y. National Comparisons : Optimal Peritoneal Dialysis Outcome among Japanese Patients[J]. Perit Dial Int, 1999, 19(S 3) : S9-S16.
  • 5Heimburger O, Waniewski J, Werynski A, et al. Peritoneal Transport in CAPD Patientswith Permanent Lossof Ultrafiltration Capacity Kidney[J]. Kidney Int, 1990,38 : 495-506.
  • 6De Vriese As,Mortier S, Lameire N H. What Happens to the Peritoneal Membrane in Long-term Peritoneal Dialysis?[J]. Perit Dial Int,2001,21(S 3):S9-S18.

二级参考文献13

  • 1韩庆烽,史均宝,范敏华.腹膜透析患者的钙磷代谢紊乱及其影响因素[J].中国血液净化,2002,1(12):4-6. 被引量:11
  • 2[5]Malluche H,Faugere M,Renal bone disease. an unmet challenge for the nephrologists. Kidny Int, 1990,38:193 - 211
  • 3[6]Sherrard D,Hercz G,Pei Y, et al. The spectrum of bone disease in end - stage renal failure - an evolving disorder kidney Int, 1993,43:436 -442
  • 4[7]Block, GA, Sakiewicz PG. Serum bicarbonate levels with sevelamer versus calcium containing phosphate binders in hemodialysis patients. Presented at ASN/ISN World Congress of Nephrology, San Francisco, CA,2001
  • 5[8]Kuster S,Ritz E,Horl W. A role for metabolic acidosis in the genesis of renal secondary hyperparathyroidism. 1n: Israel Eliahou H, Iaina A, Bar- Khayim Y,eds. Abstract Book, Ⅻ th Intenational Congress of Nephrology, Jerusalem, 1993,p.467
  • 6[9]Delmez J, Slatopolsky E, Martin K, et al. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int, 1982,21:862
  • 7[10]Chaefer K, Umlauf E, Von Herrath D, Reduced risk of hypercalcaemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis, 1992,19:460-464
  • 8[11]Sukamoto Y,Nomura M, Takahashi Y, et al. The oral 1.25- dihydroxyvitamin D3 pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron, 1991,57:23-28
  • 9[2]Blumenkrantz M, Kopple J, Moran J, et al. Metabolic balance studies and dietary protein requirements in patients undergoing CAPD. Kidney Int,1982,21:849 - 851
  • 10[3]Parker A, Nolph K. Magnesium and calcium transfer during continuous ambulary peritoneal dialysis. Trans Am Soc Artif Organs, 1980,26:194-196

共引文献3

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部